financetom
Business
financetom
/
Business
/
--Eli Lilly Wins FDA Approval for Alzheimer's Drug Kisunla
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--Eli Lilly Wins FDA Approval for Alzheimer's Drug Kisunla
Jul 2, 2024 11:06 AM

01:40 PM EDT, 07/02/2024 (MT Newswires) --

Price: 902.50, Change: -11.87, Percent Change: -1.30

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Bausch Health Q2 Adjusted Profit Declines, Revenue up 11%; Revenue Guidance Raised
Bausch Health Q2 Adjusted Profit Declines, Revenue up 11%; Revenue Guidance Raised
Aug 1, 2024
07:55 AM EDT, 08/01/2024 (MT Newswires) -- Bausch Health ( BHC ) on Thursday said adjusted profit and revenue rose in the second quarter. Adjusted profit of US$328 million compares with US$300 million last year. Bausch Health ( BHC ) reported total revenue increased 11% to US$2.4 billion. The company raised its full year revenue guidance to US$9.65 billion from...
US progressives push for Nvidia antitrust investigation
US progressives push for Nvidia antitrust investigation
Aug 1, 2024
Aug 1 (Reuters) - U.S. progressive groups and Democratic Senator Elizabeth Warren pressed the Department of Justice to investigate Nvidia ( NVDA ) over competition concerns, citing the company's dominance of the market for the chips driving the artificial-intelligence boom. Demand Progress and nine other groups wrote a letter this week urging Department of Justice antitrust chief Jonathan Kanter to...
Aptiv's Q2 Adjusted Earnings Rise, Revenue Falls; Raises 2024 Earnings Guidance; Shares Gain
Aptiv's Q2 Adjusted Earnings Rise, Revenue Falls; Raises 2024 Earnings Guidance; Shares Gain
Aug 1, 2024
08:03 AM EDT, 08/01/2024 (MT Newswires) -- Aptiv ( APTV ) reported Q2 adjusted earnings of $1.58 per diluted share on Thursday, up from $1.25 a year earlier. Analysts polled by Capital IQ expected $1.42. Revenue for the quarter ended June 30 was $5.05 billion compared with $5.20 billion a year earlier. Analysts surveyed by Capital IQ expected $5.30 billion....
Neurocrine Biosciences Q2 Adjusted Earnings, Revenue Climb -- Shares Up Pre-Bell
Neurocrine Biosciences Q2 Adjusted Earnings, Revenue Climb -- Shares Up Pre-Bell
Aug 1, 2024
08:14 AM EDT, 08/01/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) reported Q2 adjusted earnings Thursday of $1.63 per diluted share, up from $1.25 a year earlier. Analysts polled by Capital IQ expected $1.53. Revenue for the quarter ended June 30 was $590.2 million, up from $452.7 million a year earlier. Analysts polled by Capital IQ expected $546.5 million....
Copyright 2023-2026 - www.financetom.com All Rights Reserved